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Objective: Inﬂammation contributes to the development of peripheral artery disease (PAD) and may contribute to
intermittent claudication by adversely affecting vascular and skeletal muscle function. We explored the association of
inﬂammation to maximal walking time (MWT) in patients with claudication.
Methods: Circulating inﬂammatory biomarkers, including tumor necrosis factor a (TNF-a), C-reactive protein (CRP),
interleukin-6 (IL-6), and soluble intercellular adhesion molecule 1 (sICAM), were measured in 75 subjects with inter-
mittent claudication as well as in 43 healthy subjects. Real-time polymerase chain reaction was used to quantify mRNA
expression of TNF-a, IL-6, interferon-g, and CD36 from peripheral blood monocytes. Treadmill testing was performed
in PAD subjects to assess MWT.
Results: Compared with healthy subjects, PAD subjects had higher levels of circulating TNF-a (P < .0001), CRP (P [
.003), sICAM (P < .0001), and IL-6 (P < .0001). Expression of both IL-6 (P[ .024) and CD36 (P[ .018) was greater
in PAD subjects than in healthy subjects. Among subjects with PAD, higher gene expression of TNF-a was associated
inversely with MWT (P[ .01). MWT was also associated inversely with greater levels of circulating TNF-a (P[ .028),
CRP (P [ .024), IL-6 (P [ .03), and sICAM (P [ .018).
Conclusions: Systemic inﬂammation, as indicated by TNF-a inﬂammatory gene expression in peripheral blood monocytes
and by circulating biomarker levels, is associated with impairment in walking time in patients with PAD and intermittent
claudication. (J Vasc Surg 2015;61:155-61.)Inﬂammation contributes to the pathobiologic process
of atherosclerosis in patients with peripheral artery disease
(PAD) and also may contribute to the pathophysiologic
process of intermittent claudication. Insufﬁcient perfusion
resulting from hemodynamically signiﬁcant arterial stenosis
deﬁnes PAD and is required for the development of inter-
mittent claudication.1 However, because stenosis correlates
imperfectly withwalking capacity in patients with PAD, non-
hemodynamic factors affecting vascular and skeletal muscle
function may be important determinants of claudication
severity. This notion is supported by the ﬁnding that nonin-
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Previous studies have demonstrated that systemic
inﬂammation is associated with PAD. Several inﬂamma-
tory biomarkers, including high-sensitivity C-reactive
protein (hsCRP), soluble adhesion molecules (such as sol-
uble intercellular adhesion molecule [sICAM]), and tu-
mor necrosis factor a (TNF-a), are associated with both
the incidence and severity of PAD.3-6 Inﬂammation in-
creases the risk of adverse graft outcomes in PAD patients
who have undergone peripheral bypass surgery,7 and
greater systemic inﬂammation is associated with increased
cardiovascular morbidity and mortality in individuals with
PAD.8,9 The contribution of inﬂammation to the patho-
physiologic process of intermittent claudication has been
suggested by studies showing that elevated inﬂammatory
biomarkers are inversely associated with physical perfor-
mance10 and that hydroxymethylglutaryl-coenzyme A
reductase inhibitors (“statins”) improve walking time in
PAD.11,12
Circulating peripheral blood monocytes are known
drivers of the inﬂammatory milieu that promotes devel-
opment of systemic atherosclerosis.13 Whether elabora-
tion of inﬂammatory cytokines from monocytes fuels
the inﬂammatory cascade in PAD subjects and contrib-
utes to walking impairment has not been previously
explored. We examined the association of expression of
inﬂammatory genes from peripheral blood monocytes
with impaired walking time in PAD patients with
claudication.155
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Patient population. Patients with PAD, aged 40 to
85 years, were recruited as part of a randomized clinical
trial evaluating the effect of statin and thiazolidinedione
therapy on the contribution of inﬂammation and insulin
resistance to the pathophysiology of intermittent claudica-
tion (NCT00225940). Data from the initial baseline visits
were used for this analysis. A diagnosis of PAD was based
on an ankle-brachial index (ABI) measurement #0.90 at
rest in the symptomatic leg. ABI was calculated as the ratio
of the higher of the ankle systolic pressures for a given leg
and the higher of the right and left brachial artery systolic
pressures. Subjects were eligible if they had stable claudi-
cation symptoms conﬁrmed by the San Diego Claudication
Questionnaire. Patients were excluded if they had any
of the following: peripheral or coronary revascularization
within 6 months; any unstable cardiovascular process
(unstable angina, recent myocardial infarction, stroke, or
congestive heart failure); or signiﬁcant renal insufﬁciency
(serum creatinine >2.5 mg/dL). Individuals with diabetes
were included but only if they were not using insulin or
insulin-sensitizing medications. Older healthy subjects
were recruited by advertisement and were eligible if they
had no known medical problems, were taking no medica-
tions, and were not active smokers.
The study was approved by the Institutional Review
Boards at Brigham and Women’s Hospital and the Veter-
ans Administration Boston Healthcare Service from which
patients were recruited. All subjects provided written
informed consent before participation.
Study protocol. Patients with PAD included in this
analysis were among those recruited for participation in a
randomized controlled trial of the effect of reducing inﬂam-
mation and insulin resistance on walking time in patients
with intermittent claudication. Because one of the primary
study hypotheses was the effect of reducing inﬂammation
with a statin on walking time, a 4-week statin washout
period was required for all patients who were previously
taking a statin. A subset of PAD subjects who met eligibility
criteria went on to participate in the randomized portion of
the trial, the data from which are reported separately.
Baseline characteristics. Demographics and baseline
clinical history were based on self-report. Race and ethnicity
are recorded as non-Hispanic white or other. Individuals
were assigned a diagnosis of hypertension if they reported a
physician’s diagnosis of hypertension or reported use of
antihypertensive medications. Hyperlipidemia was similarly
assigned on the basis of a physician’s diagnosis or use of lipid-
lowering medications before participation. A diagnosis of
diabeteswasbasedon self-report, use of diabeticmedications,
or fasting plasma glucose concentration$126 mg/dL. Per-
sonal history of coronary artery disease, myocardial infarc-
tion, stroke, or transient ischemic attack and family history of
cardiovascular disease were all based on self-report. Smoking
status was recorded as current, former, or never smoking.
Laboratory measures. Analyses of total cholesterol,
low-density lipoprotein cholesterol, high-density lipoproteincholesterol, triglycerides, glucose, insulin, creatinine, and
complete blood count were performed by standard labora-
tory techniques. Homeostasis model assessment of insulin
resistance was calculated as fasting insulin (mmol/L) 
fasting glucose (mU/mL)/22.5. Measurement of inﬂam-
matory biomarkers was performed as follows: hsCRP con-
centration was determined by an immunoturbidimetric assay
on the Hitachi 917 analyzer (Roche Diagnostics, Indian-
apolis, Ind). Interleukin-6 (IL-6), sICAM-1, and TNF-a
receptor II (TNF-RII) were measured by enzyme-linked
immunosorbent assay from R&D Systems (Minneapolis,
Minn).
Quantiﬁcation of gene expression in peripheral
blood mononuclear cells. To measure monocyte expres-
sion of inﬂammatory genes (including TNF-a, IL-6,
interferon-g, and CD36), peripheral blood mononuclear
cells were isolated from fresh whole blood by density
gradient ultracentrifugation with Percoll. Cells were plated
on a 10-cm dish for 2 hours, after which nonadherent cells
were washed away, and the remaining monocytes were
harvested for RNA with an RNA isolation kit (Qiagen,
Valencia, Calif). For cDNA synthesis, 200 ng of RNA was
reverse transcribed (Promega, Madison, Wisc). Real-time
polymerase chain reaction was performed in a 384-well
format with the LightCyler 480 Real-Time PCR System
(Roche Diagnostics, Indianapolis, Ind) with SYBR Green I
(Bio-Rad, Carlsbad, Calif). The mRNA levels of genes of
interest were normalized to the 36B4 internal control
housekeeping gene, and relative fold change was calculated
by the DDCt method.
Treadmill walking time. Exercise testing was per-
formed in PAD subjects with a modiﬁed Gardner protocol.
Subjects walked at a constant speed of 2 mph beginning at
0% grade and increasing grade by 2% every 2 minutes.
Maximal walking time (MWT) was recorded in seconds.
To ensure reproducibility, subjects were required to perform
up to three run-in treadmill tests with <20% variability in
MWT between sequential tests to be eligible for participa-
tion. An average of the ﬁnal two run-in treadmill tests was
used as the baseline exercise measurement.
Statistical methods. Statistical analyses were per-
formed with SAS version 9.2 (SAS Institute, Inc, Cary,
NC). Categorical variables were compared by the c2 test,
and continuous variables were compared by two-sided t-
test or Wilcoxon rank sum test, depending on the normality
of the distribution. Categorical variables are expressed as
percentage and continuous variables as mean 6 standard
deviation or as median and interquartile range. Comparison
of mean values across quartiles was achieved by linear
regression. Multivariable models included age, gender,
smoking status, and ABI values as covariates. P values< .05
were considered statistically signiﬁcant.
RESULTS
Baseline characteristics. Baseline characteristics of
PAD and healthy subjects are shown in Table I. There
were 75 subjects with PAD and stable intermittent
Table I. Baseline characteristics
Baseline characteristics Healthy (n ¼ 43) PAD (n ¼ 75) P value
Age, years 58.7 6 10.0 68.5 6 7.9 <.0001
Male gender 50% 77.3% .0025
Race/ethnicity, % non-Hispanic white 88.1% 88.0% .38
Smoking (current or former) 42.9% 97.3% <.0001
Diabetes 0% 20% .0019
Coronary artery disease 0% 34.7% <.0001
Stroke 0% 20% .0019
Prior lower extremity intervention 0% 42.7% <.0001
Systolic blood pressure, mm Hg 128 6 13 152 6 21 <.0001
Diastolic blood pressure, mm Hg 80 6 8 80 6 9 .78
Waist-hip ratio 0.88 6 0.14 0.99 6 0.10 <.0001
ABI 1.13 6 0.09 0.71 6 0.16 <.0001
MWT, seconds NA 438 6 262 NA
Creatinine, mg/dL 0.87 6 0.15 1.08 6 0.3 <.0001
Glucose, mg/dL 84 6 10 107 6 42 .0008
Insulin, mg/dL 5.8 6 4.2 9.4 6 5.8 .0008
HOMA-IR 1.28 6 1.1 2.57 6 2.2 .0007
Low-density lipoprotein cholesterol, mg/dL 108 6 25 131 6 37 .0007
High-density lipoprotein cholesterol, mg/dL 55 6 16 46 6 17 .005
Triglycerides, mg/dL 107 6 71 176 6 125 .001
Total cholesterol, mg/dL 184 6 30 213 6 40 .0002
ABI, Ankle-brachial index; HOMA-IR, homeostasis model assessment of insulin resistance; MWT, maximal walking time; NA, not applicable.
Table II. Circulating inﬂammatory biomarkers
Healthy (n ¼ 43) PAD (n ¼ 75) P value
TNF-a,
pg/mL
1831 (1582-2184) 2499 (2055-3405) <.0001
hsCRP,
mg/L
1.41 (0.7-2.42) 2.49 (1.01-4.81) .003
IL-6,
pg/mL
1.11 (0.86-1.7) 2.87 (1.6-3.7) <.0001
sICAM,
ng/mL
195.4 (171.5-222.3) 257.8 (216-306) <.0001
hsCRP, High-sensitivity C-reactive protein; IL-6, interleukin-6; sICAM,
soluble intercellular adhesion molecule; TNF-a, tumor necrosis factor a.
Data are shown as median (interquartile range). Statistical comparisons
achieved by Wilcoxon rank sum test.
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inclusion in this analysis. Subjects with PAD were older
(68.5 6 7.9 vs 58.8 6 10.0 years; P < .0001) and had
higher resting blood pressure and glucose and insulin levels
and more abnormal cholesterol proﬁles than healthy sub-
jects (Table I). By the nature of the eligibility criteria, no
healthy subjects had any underlying medical conditions. Of
the subjects with PAD, diabetes was present in 20.0% and
coronary artery disease in 34.7%; 42.7% had undergone
prior lower extremity revascularization.
Inﬂammatory biomarkers. PAD subjects had signiﬁ-
cantly higher levels of biomarkers of inﬂammation com-
pared with healthy subjects (Table II). In PAD vs healthy
subjects, respectively, the median level of TNF-a was 2499
pg/mL (IQR, 2055-3405) vs 1831 pg/mL (IQR, 1582-
2184; P < .0001); hsCRP was 2.49 mg/L (IQR, 1.01-
4.81) vs 1.41 mg/L (IQR, 0.7-2.42; P ¼ .003); sICAM
was 257.8 ng/mL (IQR, 216-306) vs 195.4 ng/mL
(IQR, 171.5-222.3; P< .0001); and IL-6 was 2.87 pg/mL
(IQR, 1.6-3.7) vs 1.11 pg/mL (IQR, 0.86-1.7; P< .0001).
Gene expression in peripheral blood monocytes.
Expression of inﬂammatory genes was measured in periph-
eral blood monocytes obtained from a subset of PAD sub-
jects (n ¼ 49) and healthy volunteers (n ¼ 9). There were
no qualitative differences in the baseline characteristics of
these patients compared with the groups as a whole. There
was signiﬁcantly higher expression of IL-6 (relative
expression, 1.85 [IQR, 0.86-3.81] vs 0.74 [IQR, 0.38-
1.53]; P ¼ .024) and CD36 (1.99 [IQR, 1.25-3.04] vs
0.79 [IQR, 0.43-1.37]; P ¼ .018) in PAD compared with
healthy subjects. There was no signiﬁcant difference in
expression of TNF-a or interferon-g in patients with PAD
compared with healthy subjects (Table III). There was no
signiﬁcant correlation between monocyte gene expressionand circulating biomarker levels (for TNF-a: r ¼ 0.22; P ¼
.13; and for IL-6: r ¼ 0.15; P ¼ .33).
Association of gene expression and inﬂammatory
markers with walking time. We explored whether expres-
sion of inﬂammatory genes in peripheral blood monocytes
and circulating biomarker levels were associated with
walking time in subjects with PAD. Average MWT among
PAD subjects was 438 6 262 seconds. As shown in Fig 1,
monocyte TNF-a gene expression was associated inversely
with MWT. Relative TNF-a expression levels were highest
in those patients in the lowest quartile of walking time.
Increasingly lower expression was noted in PAD subjects
with greater walking time (1.69 6 1.29 in quartile 1,
1.30 6 0.90 in quartile 2, 1.13 6 0.58 in quartile 3, and
0.88 6 0.38 in quartile 4; P ¼ .016). This relationship
persisted even after adjustment for age, gender, and
smoking status (P ¼ .04), although it was no longer sig-
niﬁcant after adjustment for ABI (P ¼ .10). There was no
Table III. Gene expression in peripheral blood
monocytes
Healthy (n ¼ 9) PAD (n ¼ 49) P value
TNF-a 0.72 (0.49-1.07) 1.1 (0.66-1.56) .27
IL-6 0.74 (0.38-1.53) 1.85 (0.86-3.81) .024
IFN-g 0.67 (0.31-1.23) 0.39 (0.07-1.30) .19
CD36 0.79 (0.43-1.37) 1.99 (1.25-3.04) .018
IFN-g, interferon-g; IL-6, interleukin-6; TNF-a, tumor necrosis factor a.
Data shown as median (interquartile range). Statistical comparisons ach-
ieved by Wilcoxon rank sum test.
Fig 1. The association between walking time and expression of
tumor necrosis factor (TNF) a in patients with peripheral artery
disease (PAD). Subjects were divided by quartile of maximal
walking time (MWT), and comparison of mean values across
quartiles was achieved by linear regression. Data are shown as
mean 6 standard deviation.
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other inﬂammatory genes in monocytes.
Circulating levels of TNF-a were also signiﬁcantly asso-
ciated with walking time in subjects with PAD (P ¼ .028;
Fig 2). MWT was lowest in those subjects with the highest
levels of circulating TNF-a (531 6 323 seconds in quartile
1, 522 6 288 seconds in quartile 2, 385 6 270 seconds in
quartile 3, and 309 6 158 seconds in quartile 4). A similar
relationship was noted between MWT and circulating
hsCRP (P ¼ .028), IL-6 (P ¼ .03), and sICAM (P ¼
.018; Fig 2). The associations between all circulating in-
ﬂammatory biomarkers and MWT remained signiﬁcant
even after adjustment for age, gender, smoking status, dia-
betes, and ABI (for TNF-a, P ¼ .002; for hsCRP, P ¼
.037; for IL-6, P ¼ .01; and for sICAM, P ¼ .0028). Using
linear regression, we found that there was a signiﬁcant rela-
tionship between MWT and TNF-a (P ¼ .012), IL-6 (P ¼
.004), hsCRP (P ¼ .04), and sICAM (P ¼ .005). These
data remained statistically signiﬁcant even after multivari-
able adjustment for age, gender, smoking status, and ABI
for TNF-a (P ¼ .003), IL-6 (P ¼ .004), and sICAM
(P ¼ .0002) but not for hsCRP (P ¼ .058).
DISCUSSION
Systemic inﬂammation promotes the development and
progression of PAD. Peripheral blood monocytes are key
players in the pathogenesis of atherosclerotic plaque forma-
tion,13 and monocyte-derived proinﬂammatory cytokines
may exacerbate the inﬂammatory cascade that fosters
atherosclerosis in patients with PAD. Whether monocyte-
derived inﬂammatory cytokines contribute to impaired
functional capacity in patients with PAD has not been pre-
viously explored. Here we demonstrate that monocyte
mRNA expression of the proinﬂammatory cytokine TNF-
a is associated with impaired MWT in patients with PAD
and intermittent claudication. We also demonstrate that
circulating levels of proinﬂammatory cytokines, including
TNF-a, hsCRP, IL-6, and sICAM, are signiﬁcantly
elevated in patients with PAD and also correlate strongly
with impaired MWT, even after adjustment for demo-
graphic parameters, atherosclerotic risk factors including
smoking and diabetes, and degree of hemodynamic steno-
sis as indicated by the ABI.
Intermittent claudication and, importantly, improve-
ment in symptoms in response to therapies such as exercisetraining do not necessarily relate to changes in the severity
of arterial stenosis, raising questions about other contribu-
tors to symptomatic PAD and other mechanisms by which
known therapies afford a clinical beneﬁt. Inﬂammation,
including release of cytokines from peripheral blood mono-
cytes, may contribute to claudication itself. One can theo-
rize that monocytes promote an inﬂammatory cascade
leading to impaired vascular function in the lower extrem-
ities, worsening insulin resistance, and advancing skeletal
muscle dysfunctiondall factors that may contribute to
claudication.14-16 In patients with PAD, routine daily phys-
ical activity, in and of itself, may also exacerbate the inﬂam-
matory state, as skeletal muscle injury from repetitive limb
ischemia with walking can increase circulating levels of cy-
tokines and adhesion molecules, increasing oxidant stress
and endothelial dysfunction.17-19 Acute physical activity
in patients with PAD also increases the local proportion
of activated neutrophils and myeloperoxidase content,
additional markers of oxidant stress and inﬂammation, in
the affected limb speciﬁcally.20-22 Taken together, overex-
pression of proinﬂammatory genes in peripheral blood
monocytes as demonstrated in our study may be both a
cause and a result of impaired walking in patients with
PAD.
The importance of reducing inﬂammation as a poten-
tial therapeutic target for patients with claudication is sup-
ported by several clinical trials of statin therapy to improve
impaired walking time in PAD. Statins, known to reduce
systemic inﬂammation, have been shown to improve
walking time in individuals with claudication,11,12,23
although there are conﬂicting data from trials using lower
Fig 2. The association between maximal walking time (MWT) and circulating inﬂammatory biomarkers, including
tumor necrosis factor a (TNFa), high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and soluble inter-
cellular adhesion molecule (sICAM). Comparisons of MWT across biomarker quartiles was achieved by linear
regression. Data for MWT are shown as mean 6 standard deviation. Quartiles values for inﬂammatory biomarkers are
as follows: for TNF-a, Q1: 2025.7 pg/mL, Q2: 2025.7-2528.6 pg/mL, Q3: 2528.6-3592.4 pg/mL, and
Q4:$3592.4pg/mL; for hsCRP,Q1:<1.01mg/L,Q2:1.01-2.47mg/L,Q3:2.47-4.81mg/L, andQ4:$4.81mg/L;
for sICAM, Q1: < 214.7 ng/mL, Q2: 214.7-255.3 ng/mL, Q3: 255.3-295.4 ng/mL, and Q4: $ 295.4 ng/mL; and
for IL-6, Q1:< 1.61 pg/mL, Q2: 1.61-2.87 pg/mL, Q3: 2.87-3.49 pg/mL, and Q4:$ 3.49 pg/mL.
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contribution of inﬂammation to impaired physical func-
tioning has also been suggested from cross-sectional studies
in patients with PAD, both with and without claudication,
in whom biomarkers of inﬂammation, such as CRP, D-
dimer, and ﬁbrinogen, are associated with poorer perfor-
mance on the 6-minute walk test and other measures of
strength and mobility.10 Our study differs from this prior
work in that it is the ﬁrst to explore gene expression in
monocytes, a cell type recognized to be a source of circu-
lating inﬂammatory biomarkers, and uses exercise treadmill
testing as a “gold standard” measure of functional capacity
in PAD patients.
There are several limitations to this work that merit
consideration. We did not ﬁnd a signiﬁcant correlation
between expression of proinﬂammatory genes in mono-
cytes and circulating levels of inﬂammatory biomarkers.
The source of elevated circulating inﬂammatory bio-
markers in PAD is no doubt multifactorial. Thus, the
lack of a signiﬁcant association between monocyte
expression and circulating levels of these biomarkers
may reﬂect the fact that peripheral blood monocytes are
only one of several sources of production of circulating
inﬂammatory biomarkers, with tissue-based monocytes
also contributing to the inﬂammatory milieu. Failure to
detect a signiﬁcant association also may reﬂect the smallsample size. In addition, in this cross-sectional analysis,
we cannot determine whether monocyte TNF-a gene
expression is a direct cause of impaired walking time,
whether limitations in physical activity in patients with
PAD may be the primary driver of increased inﬂammation
and insulin resistance, or whether inﬂammation may be
exacerbated by acute bouts of physical activity in patients
with PAD.26-29 Nevertheless, these data do support the
prospect that modulation of inﬂammation, and specif-
ically inﬂammation in monocytes, might have a favorable
impact on PAD and claudication symptoms. Finally, we
recognize that there are differences in clinical characteris-
tics beyond the presence of PAD alone that may account
for some of the differences in gene expression in PAD
subjects compared with healthy subjects. It is not possible
to separate the effects of age and other comorbid diseases
that, by deﬁnition, were more prevalent in the PAD pop-
ulation. Future studies with additional comparator
groups, such as individuals with other manifestations of
atherosclerosis but not involving the lower extremities,
would be required to discern whether the ﬁndings are
attributable to PAD or to other related factors.
CONCLUSIONS
During the last several decades, there has been increasing
understanding of the contribution of inﬂammation to the
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known to be associated with the initial development of
PAD, contributes to adversemorbidity andmortality in indi-
viduals with PAD, and portends worse outcomes in PAD
subjects undergoing peripheral bypass surgery, including
restenosis and graft failure.4,5,7-9,31 Inﬂammatorymediators,
including TNF-a, also promote skeletal muscle wasting,
resulting in decreased muscle mass and strength.32,33 Here
we demonstrate a clear association of walking impairment
with circulating inﬂammatory biomarkers and with mono-
cyte expression of the inﬂammatory gene TNF-a. Whether
monocyte overactivation can be ameliorated with our exist-
ing therapies for claudication, such as exercise training,
merits further evaluation, as suggested by our data here.
It has become increasingly clear that the pathophysio-
logic process of intermittent claudication is multifactorial.
Hemodynamic stenosis resulting from atherosclerotic pla-
que is necessary for development of claudication, but future
studies are required to better understand the relative
contribution of nonhemodynamic factors, such as inﬂam-
mation, to intermittent claudication. Improved under-
standing of these factors will, it is hoped, guide the
development of novel targeted therapies to improve func-
tional impairment in patients with PAD.
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